Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neurotrope, Inc.NTRP · Entity 144906 | Director | December 01, 2020 | December 03, 2020 |
| TAO Synergies Inc.TAOX · Entity 7482 | Director | May 18, 2026 | May 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neurotrope, Inc.
Report date December 01, 2020 · Filed December 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.00 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-01 · Disposition to issuer · Disposed 9,375 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.52 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-12-01 · Disposition to issuer · Disposed 1,563 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.04 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-01 · Disposition to issuer · Disposed 1,563 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.56 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-12-01 · Disposition to issuer · Disposed 15,535 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.10 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.91 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-12-01 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.06 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-12-01 · Disposition to issuer · Disposed 72,500 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
TAO Synergies Inc.
Report date May 18, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 · Expires 2036-05-18 | Direct | 35,000 |
Reported balance
After 2026-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-18 · Grant · Acquired 35,000 · Balance 35,000 F1: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following May 18, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following May 18, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2026 Filed May 19, 2026 22:44 UTC | TAO Synergies Inc. TAOX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001104659-26-063993 · tm2615135-3_4seq1.xml · derivative · entry 1 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock, par value $0.0001 per share · 35,000 shares Expires 2036-05-18 F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following May 18, 2026. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:02 UTC | TAO Synergies Inc. TAOX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 800 | $0.00 Strike: $5.52 | $0.00 |
DisclosureSEC source: 0001104659-26-040887 · tm2611352-3_4seq1.xml · derivative · entry 1 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800 Underlying: Common Stock, par value $0.0001 per share · 800 shares Expires 2036-04-07 F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following April 7, 2026. Read SEC document |
| October 17, 2025 Filed Oct 17, 2025 21:13 UTC | TAO Synergies Inc. TAOX · Entity 7482 | Tax withholdingCommon Stock, par value $0.0001 per share | 6,000 | $7.23 | $43,380.00 |
DisclosureSEC source: 0001104659-25-100463 · tm2529010-5_4seq1.xml · nonDerivative · entry 2 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,566 F2 · shares: Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction. Read SEC document |
| October 17, 2025 Filed Oct 17, 2025 21:13 UTC | TAO Synergies Inc. TAOX · Entity 7482 | GrantCommon Stock, par value $0.0001 per share | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-100463 · tm2529010-5_4seq1.xml · nonDerivative · entry 1 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,566 F1 · balance_after: Includes (i) 15,000 restricted stock units granted on October 17, 2025, under TAO Synergies Inc.'s (the "Issuer") 2020 Equity Incentive Plan which vested immediately and (ii) 10,566 shares of common stock. Read SEC document |
| August 06, 2025 Filed Oct 17, 2025 21:13 UTC | TAO Synergies Inc. TAOX · Entity 7482 | GrantEmployee Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001104659-25-100463 · tm2529010-5_4seq1.xml · derivative · entry 3 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2035-07-14 F3 · date: The option grant was approved by a committee of the Issuer's board of directors on July 14, 2025 subject to shareholder approval of an amendment to the Company's 2020 Equity Incentive Plan (the "Plan") to increase the number of shares authorized for issuance of awards under the Plan. The Company received shareholder approval of the amendment to the Plan on August 6, 2025. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:07 UTC | TAO Synergies Inc. TAOX · Entity 7482 | Tax withholdingCommon Stock, par value $0.0001 per share | 6,164 | $7.85 | $48,387.40 |
DisclosureSEC source: 0001104659-25-065283 · tm2519649-6_4seq1.xml · nonDerivative · entry 2 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,566 F2 · shares: Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:07 UTC | TAO Synergies Inc. TAOX · Entity 7482 | GrantCommon Stock, par value $0.0001 per share | 15,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-065283 · tm2519649-6_4seq1.xml · nonDerivative · entry 1 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,730 F1 · balance_after: Includes (i) 15,410 restricted stock units granted on June 30, 2025, under the Issuer's 2020 Equity Incentive Plan which vested immediately upon issuance and (ii) 1,320 shares of common stock. Read SEC document |
| April 03, 2025 Filed Apr 7, 2025 21:01 UTC | TAO Synergies Inc. SNPX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 800 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001104659-25-032683 · tm2511539-4_4seq1.xml · derivative · entry 1 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800 Underlying: Common Stock, par value $0.0001 per share · 800 shares Expires 2035-04-03 F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following April 3, 2025. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 20:08 UTC | TAO Synergies Inc. SNPX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 800 | $0.00 Strike: $5.39 | $0.00 |
DisclosureSEC source: 0001104659-24-045805 · tm2411531-4_4seq1.xml · derivative · entry 1 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800 Underlying: Common Stock, par value $0.0001 per share · 800 shares Expires 2034-04-08 F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following April 8, 2024. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 20:17 UTC | TAO Synergies Inc. SNPX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001104659-23-040197 · tm2311075-3_4seq1.xml · derivative · entry 1 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock, par value $0.0001 per share · 20,000 shares Expires 2033-03-29 F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following March 29, 2023. Read SEC document |
| December 16, 2022 Filed Dec 21, 2022 01:02 UTC | TAO Synergies Inc. SNPX · Entity 7482 | SaleCommon Stock, par value $0.0001 per share | 27,000 | $1.17 | $31,641.30 |
DisclosureSEC source: 0001104659-22-128772 · tm2233089-7_4seq1.xml · nonDerivative · entry 1 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 F1 · shares: Shares sold pursuant to a Rule 10b5-1 sales plan, entered into on December 6, 2021 and amended and restated on October 24, 2022, to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 21:02 UTC | TAO Synergies Inc. SNPX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 96,000 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001104659-22-119877 · tm2230820-3_4seq1.xml · derivative · entry 1 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,000 Underlying: Common Stock, par value $0.0001 per share · 96,000 shares Expires 2032-11-15 F1 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer. Read SEC document |
| November 15, 2022 Filed Dec 2, 2022 00:51 UTC Amendment | TAO Synergies Inc. SNPX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001104659-22-123803 · tm2231816-5_4aseq1.xml · derivative · entry 1 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock, par value $0.0001 per share · 75,000 shares Expires 2032-11-15 F1 · shares: This filing amends the Form 4, filed on November 17, 2022 by Mr. Singer to reflect the lower number of options allowed to be granted pursuant to the per-participant grant limit contained in the Issuer's 2020 Equity Incentive Plan, as amended. F2 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer. Read SEC document |
| April 05, 2022 Filed Apr 6, 2022 21:02 UTC | TAO Synergies Inc. SNPX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001104659-22-043277 · tm2212026-4_4seq1.xml · derivative · entry 1 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock, par value $0.0001 per share · 1,500 shares Expires 2032-04-05 F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following April 5, 2022. Read SEC document |
| April 05, 2022 Filed Jun 23, 2022 22:01 UTC Amendment | TAO Synergies Inc. SNPX · Entity 7482 | OtherStock Option (Right to Buy) · Derivative | 0 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-073973 · tm2219110-4_4aseq1.xml · derivative · entry 1 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 per share · Not disclosed shares Expires not disclosed F1 · security: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · derivative.exercise_price: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · kind: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · shares: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · price: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · derivative.exercise_date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · derivative.expiration_date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · derivative.underlying: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · derivative.underlying_shares: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · balance_after: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · ownership.direct: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Singer, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 22:08 UTC | TAO Synergies Inc. SNPX · Entity 7482 | GrantCommon Stock, par value $0.0001 per share | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-092721 · tm2122331-7_4seq1.xml · nonDerivative · entry 1 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 F1 · balance_after: Includes 60,000 restricted stock units granted on July 13, 2021 (the "Grant Date") under the Issuer's 2020 Equity Incentive Plan which will vest 50% on the six month anniversary of the Grant Date and the remaining 50% on the one year anniversary of the Grant Date. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:40 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 72,500 | Not disclosed Strike: $0.97 | Not disclosed |
DisclosureSEC source: 0001104659-20-132151 · tm2037705d4_4.xml · derivative · entry 10 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,500 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:40 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $0.82 | Not disclosed |
DisclosureSEC source: 0001104659-20-132151 · tm2037705d4_4.xml · derivative · entry 9 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:40 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $4.06 | Not disclosed |
DisclosureSEC source: 0001104659-20-132151 · tm2037705d4_4.xml · derivative · entry 8 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:40 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $3.93 | Not disclosed |
DisclosureSEC source: 0001104659-20-132151 · tm2037705d4_4.xml · derivative · entry 7 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:40 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $8.91 | Not disclosed |
DisclosureSEC source: 0001104659-20-132151 · tm2037705d4_4.xml · derivative · entry 6 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:40 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $19.10 | Not disclosed |
DisclosureSEC source: 0001104659-20-132151 · tm2037705d4_4.xml · derivative · entry 5 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:40 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 15,535 | Not disclosed Strike: $10.56 | Not disclosed |
DisclosureSEC source: 0001104659-20-132151 · tm2037705d4_4.xml · derivative · entry 4 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,535 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:40 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 1,563 | Not disclosed Strike: $71.04 | Not disclosed |
DisclosureSEC source: 0001104659-20-132151 · tm2037705d4_4.xml · derivative · entry 3 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,563 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:40 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 1,563 | Not disclosed Strike: $35.52 | Not disclosed |
DisclosureSEC source: 0001104659-20-132151 · tm2037705d4_4.xml · derivative · entry 2 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,563 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:40 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 9,375 | Not disclosed Strike: $32.00 | Not disclosed |
DisclosureSEC source: 0001104659-20-132151 · tm2037705d4_4.xml · derivative · entry 1 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,375 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| November 24, 2020 Filed Nov 27, 2020 17:08 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 72,500 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001104659-20-130076 · tm2037145-4_4seq1.xml · derivative · entry 1 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,500 Underlying: Common Stock · 72,500 shares Expires 2030-11-24 F1 · derivative.exercise_date: The shares will immediately vest and become exercisable subject to and upon consummation of (1) the merger of PM Merger Sub 1, LLC with and into Metuchen Pharmaceuticals, LLC ("Metuchen"), with Metuchen surviving as a wholly-owned subsidiary of Petros Pharmaceuticals, Inc. ("Petros") and (2) the merger of PN Merger Sub 2, Inc. with and into Neurotrope, Inc. ("Neurotrope"), with Neurotrope surviving as a wholly-owned subsidiary of Petros (together, the "Mergers"). F2 · derivative.expiration_date: In the event the reporting person departs from the board of directors following the consummation of the Mergers, the options shall expire on the date that is one year from the date of the consummation of the Mergers. Read SEC document |
| March 20, 2020 Filed Mar 24, 2020 18:00 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001104659-20-037864 · tm2013506d2_4.xml · derivative · entry 1 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-03-20 F1 · security: The stock option award was made in connection with the Issuer's annual equity grants to non-employee directors pursuant to the terms of the Neurotrope, Inc. 2017 Equity Incentive Plan. Read SEC document |
| March 15, 2019 Filed Apr 15, 2019 17:00 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.06 | $0.00 |
DisclosureSEC source: 0001144204-19-019713 · tv518876_4.xml · derivative · entry 1 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-03-15 F1 · security: The stock option award was made in connection with the Issuer's annual equity grants to non-employee directors pursuant to the terms of the Neurotrope, Inc. 2017 Equity Incentive Plan. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 18:02 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.93 | $0.00 |
DisclosureSEC source: 0001144204-19-002686 · tv511526_4.xml · derivative · entry 1 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-01-22 F1 · security: The stock option award was made pursuant to the terms of the Neurotrope, Inc. 2017 Equity Incentive Plan. The stock options shall vest according to the following schedule: 50% vest on the date of grant, with the remaining stock options vesting in equal quarterly installments over a two-year period following the date of grant. F1 · derivative.exercise_date: The stock option award was made pursuant to the terms of the Neurotrope, Inc. 2017 Equity Incentive Plan. The stock options shall vest according to the following schedule: 50% vest on the date of grant, with the remaining stock options vesting in equal quarterly installments over a two-year period following the date of grant. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 17:00 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $8.91 | $0.00 |
DisclosureSEC source: 0001144204-18-014955 · tv488493_form4.xml · derivative · entry 1 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-03-13 F1 · shares: Represents the annual option grant to each of the Issuer's non-employee directors on the fifth business day after the Issuer's filing of its Annual Report on Form 10-K pursuant to the Issuer's Nonemployee Director Compensation Policy. Read SEC document |
| March 17, 2017 Filed Mar 21, 2017 21:51 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $19.10 | $0.00 |
DisclosureSEC source: 0001144204-17-015930 · v462253_4.xml · derivative · entry 1 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-03-17 F1 · security: Represents the annual option grant to each of the Issuer's non-employee directors on the fifth business day after the Issuer's filing of its Annual Report on Form 10-K pursuant to the Issuer's Nonemployee Director Compensation Policy. Such option grant is subject to stockholder approval of the Issuer's 2017 Equity Incentive Plan under which the option was granted. Read SEC document |
| November 21, 2016 Filed Nov 23, 2016 17:03 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option · Derivative | 497,096 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001144204-16-136407 · v453763_4.xml · derivative · entry 1 Singer William S. · CIK 0001617927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 497,096 Underlying: Common Stock · 497,096 shares Expires 2026-11-21 F2 · price: These options were granted in connection with the Issuer's grant to certain officers, directors and employees following the final closing of a private placement on November 21, 2016. F1 · derivative.exercise_date: One half of the stock options vest immediately upon grant and the remaining one half vest in equal daily installments over a four-year period beginning on the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.